Top AI companies in Tel Aviv

About Compugen Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable AI/ML powered computational discovery platform (UnigenTM) to identify novel drug targets and biological pathways for developing cancer immunotherapies. Compugen has two differentiated Fc-reduced programs targeting TIGIT: COM902, a fully owned potential best-in-class Fc-reduced high affinity anti-TIGIT antibody in Phase 1 development and rilvegostomig, an Fc-reduced PD-1/TIGIT bispecific antibody in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. The TIGIT component of rilvegostomig is derived from COM902. In Phase 1 development Compugen has COM701, a potential first-in-class anti-PVRIG Fc-reduced antibody and GS-0321 (previously COM503), a potential first-in-class, high affinity anti-IL-18 binding protein antibody, licensed to Gilead. In addition, the Company’s therapeutic pipeline of early-stage immuno-oncology programs consists of research programs aiming to address new mechanisms to activate the immune system against cancer. Compugen's offices are located in Israel. Compugen’s shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN

• Post-IPO equity
• 113 employees
• Founded 1993

CytoReason is a tech company transforming biopharma’s decision-making from trial and error to data-driven using an AI Platform of computational disease models. With its extensive database of public and proprietary data, the company maps human diseases – tissue by tissue and cell by cell. Researchers of all levels rely on CytoReason’s technology to make data-driven decisions across the drug development life cycle. Scientists can identify potential targets, prioritize indications, and stratify patient populations. Program leaders can compare drugs across multiple diseases or multiple drugs within a single disease. C-level executives can gain valuable tools to manage and optimize entire drug portfolios.

• Series B
• 103 employees
• Founded 2016

Syqe Medical is a clinical-stage pharma-tech company redefining the global standard of care for central nervous system (CNS) therapeutics. Founded in 2011 and headquartered in Tel Aviv, we are unlocking the therapeutic potential of CNS molecules through a first-in-class precision ambulatory drug delivery platform.Solving the Dose-Impairment TradeoffFor decades, the medical application of potent compounds (such as Δ9-THC) has been hindered by a fundamental compromise: effective relief often comes at the cost of debilitating psychoactive side effects. Syqe is solving this problem. Our proprietary drug-device combination provides consistent sub-hallucinogenic dosing (down to 100-microgram resolution) to effectively decouple therapeutic efficacy from cognitive impairment. This empowers patients to achieve rapid, sustained symptom relief while maintaining complete daily functionality.Making Medical History: The Path to FDA ApprovalWe are on a definitive regulatory pathway to make history: securing the world's first FDA approval for a precision-inhaled botanical CNS therapeutic. Currently in global Phase 2 clinical trials for Diabetic Peripheral Neuropathic Pain (DPNP) - a massive unmet medical need. Following our lead indication, our clinical strategy is designed for rapid indication expansion into treatments for PTSD, insomnia, and chronic lower back pain.A Battle-Tested Standard of Care for VeteransOur technology is already clinically de-risked by unprecedented real-world evidence. Today, the commercially available SyqeAir platform is fully adopted and reimbursed by the Israeli Ministry of Defense (MOD) as a first-line treatment for veterans suffering from severe PTSD and chronic pain. Functioning as a rapid-response shield against trauma, our platform allows wounded warriors to successfully return to the workforce without the impairment associated with traditional treatments, sleep better at night, and reduces conventional dosages by two order of magnitude.

• Private equity
• 91 employees
• Founded 2011

Bar Ilan Institute for Nanotechnology and Advanced materials

• 77 employees
• Founded 2007

הפקולטה למדעי הרפואה והבריאות ע"ש גריי באוניברסיטת תל-אביב היא הפקולטה לרפואה הגדולה בישראל. הקהילה שלנו המורכבת מסטודנטים, חוקרים, מדענים, רופאים וקלינאים פועלת בכל תחומי מדעי הבריאות והביו-רפואה ברמה המתקדמת ביותר. החזון שלנו משלב מצוינות וחדשנות בהוראה ובמחקר. מטרתנו העיקרית היא לשלב את הטיפול הרפואי המתקדם עם צרכי המטופלים, בחמלה ובמקצוענות הנדרשת. הפקולטה מונה כ-2000 חברי סגל העוסקים בהוראה ומחקר בקמפוס באוניברסיטת תל-אביב ובמחלקות המסונפות במרכזים רפואיים גדולים, בבתי-החולים הפסיכיאטריים, במרכזי שיקום ובמרפאות קהילתיות באזור תל-אביב רבתי. תכניות ההכשרה והלימוד המגוונות בפקולטה מועברות ע"י סגל אקדמי של מומחים בתחומם.

• 69 employees
• Founded 1964